Get started

Healthcare

$MASS, growth stock close to breakout908 Devices Inc is in the Medical-Research Eqp/Svc Group. It develops analytical devices for chemical and biomoecular solutions. The price made a shortfall within the channel that has been forming since January. This shortfall may signal a breakout in the right direction. I would buy it with a target sell at its next resistance level which is at $29, that's a +20% profit. Play this trade with your own risk/reward strategy. I'm sure I will. Also just recently, the company tweeted: "Proud to share our #MX908 device was chosen by the U.S. Army to provide chemical identification in their #AugmentedReality training program, ensuring optimal safety when encountering unidentified substances".
NASDAQ:MASSLong
by dpuleo19
3M Company (MMM) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the US company 3M Company (MMM). The 3M Company is an American multinational conglomerate corporation operating in the fields of industry, worker safety, U.S. health care, and consumer goods. The company produces over 60,000 products under several brands, including adhesives, abrasives, laminates, passive fire protection, personal protective equipment, window films, paint protection films, dental and orthodontic products, electrical and electronic connecting and insulating materials, medical products, car-care products,electronic circuits, healthcare software and optical films. The Falling Wedge has broken through the resistance line on 27/07/2022, if the price holds above this level, you can have a possible bullish price movement with a forecast for the next 27 days towards 155.52 USD. Your stop-loss order, according to experts, should be placed at 125.60 USD if you decide to enter this position. 3M Co. said it would spin off its healthcare business as a public company and sought bankruptcy protection for a subsidiary that once produced military earplugs that thousands of veterans now blame for damaging their hearing. The moves Tuesday attempt to address the industrial conglomerate’s lingering overhangs with sluggish growth of its businesses and an increasing exposure to costs for lawsuits. The company said it has committed $1 billion to fund a trust to pay claims about its earplugs and $240 million to fund expected expenses related to the cases. 3M said it would provide more funding if required. The company filed for bankruptcy for Aearo Technologies, a subsidiary that once made the earplugs, as a way to fence off the litigation from the rest of 3M. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
NYSE:MMMLong
by legacyFXofficial
1
The health care sector ($XLV) is looking bullish!Notes: * It seems like the health care sector is making an inverse head and shoulders pattern. * A break out from this pattern could mean that health care stocks lead the market and the sector may see new all-time-highs. * Be on the lookout for trade ideas in this sector as it's showing tonnes of accumulation recently * You may also look to buy the sector ETF if it makes a daily close above the white trend line with higher than average volume.
AMEX:XLVLong
by HaseebKhan_90
Green in the sea of red: Biotech (2)Summary This week we are sharing 2 rebound trade opportunities in healthcare and biotech, AMEX:XLV and AMEX:XBI , which are showing relative strength against S&P500 and Nasdaq , making them better candidates to trade for rebound. Since the beginning of 2022, skyrocketing inflation and increasing recession risk have pushed the broad equity markets to the downside. S&P500 is down more than 20% from peak, while the more tech heavy Nasdaq is down close to 30% from peak as of today. If we look back the whole rally, it all started during Mar-2020 as the Fed reacted aggressively toward covid by massive money printing (i.e. quantitative easing). In fact both S&P500 and Nasdaq are now getting closer to the 250 weeks moving average, which is approximately where the post-covid rally had broken the pre-covid peak. Rebound is very likely to happen as “where it started” is usually a strong resistance level that slows correction. S&P500 Nasdaq100 To execute this trade, instead of directly longing the indexes, healthcare and biotech sector ETF, AMEX:XLV and AMEX:XBI are showing relative strength against S&P500 and Nasdaq100, which make them better candidates to trade the idea. Fundamentally speaking, we believe the reason behind the strength is due to the irreversible trends of aging population across the globe especially among developed countries; as well as in the seemingly more frequent pandemic outbreaks during recent years. Both trends create steady demand for healthcare and need for biotechnological innovation. The MRNA technology is a good recent example to illustrate the importance of biotechnological innovation in fighting pandemic. We recommend more conservative traders to execute the idea with AMEX:XLV (link here: ), while more aggressive traders can go with AMEX:XBI (this post) which is relatively volatile. Note : XBI also come with 3X leveraged ETF AMEX:LABU (bullish) and AMEX:LABD (bearish) for those who are looking for more leverage with same amount of capital Technical The 250 days moving average of AMEX:XBI is pointing downward, and it is currently trading below the 250 days moving average, which confirms the down trend is still effective for AMEX:XBI . Benchmarking with NASDAQ:QQQ (Nasdaq100 index ETF), although both are in similar down trend, AMEX:XBI 20 days moving average has already crossed the 50 days moving average while that of NASDAQ:QQQ still running below, which shows stronger confirmation of the rebound for AMEX:XBI than NASDAQ:QQQ . Here are some important level one should pay attentions to: Downside support 72.55: Jun-30 retest low after breaking 50 days moving average 61.78: May-12 52 weeks low Upside resistance 84.63: Jul-8 high after breaking 50 days moving average 97.19: Apr-5 high before creating new low on May-12 118.23: 2021 May-10 consolidation bottom, which was broken, retested and continued to the downside during 2021 Nov to Dec
AMEX:XBILong
by geoffreyip523
Green in the sea of red: Healthcare (1)Summary This week we are sharing 2 rebound trade opportunities in healthcare and biotech, AMEX:XLV and AMEX:XBI , which are showing relative strength against S&P500 and Nasdaq , making them better candidates to trade for rebound. Since the beginning of 2022, skyrocketing inflation and increasing recession risk have pushed the broad equity markets to the downside. S&P500 is down more than 20% from peak, while the more tech heavy Nasdaq is down close to 30% from peak as of today. If we look back the whole rally, it all started during Mar-2020 as the Fed reacted aggressively toward covid by massive money printing (i.e. quantitative easing). In fact both S&P500 and Nasdaq are now getting closer to the 250 weeks moving average, which is approximately where the post-covid rally had broken the pre-covid peak. Rebound is very likely to happen as “where it started” is usually a strong resistance level that slows correction. S&P500 Nasdaq100 To execute this trade, instead of directly longing the indexes, healthcare and biotech sector ETF, AMEX:XLV and AMEX:XBI are showing relative strength against S&P500 and Nasdaq100, which make them better candidates to trade the idea. Fundamentally speaking, we believe the reason behind the strength is due to the irreversible trends of aging population across the globe especially among developed countries; as well as in the seemingly more frequent pandemic outbreaks during recent years. Both trends create steady demand for healthcare and need for biotechnological innovation. The MRNA technology is a good recent example to illustrate the importance of biotechnological innovation in fighting pandemic. We recommend more conservative traders to execute the idea with AMEX:XLV (this post), while more aggressive traders can go with AMEX:XBI (link here: ) which is relatively volatile. Note : XBI also come with 3X leveraged ETF AMEX:LABU (bullish) and AMEX:LABD (bearish) for those who are looking for more leverage with same amount of capital Technical AMEX:XLV is still outperforming major indexes. Instead of downtrend, AMEX:XLV is still in a consolidation period. AMEX:XLV has been trading in extending box range since Oct-2021, with 1 extension to the upside in Dec-2021, and 1 extension to the downside this year on Jun-13. The more than 8 months of consolidation period has flattened the 250 days moving average, yet not bending it downward (yet?). 20 days and 50 days moving averages have been crossing each other multiple times during the consolidation period, making them less indicative from a technical perspective. Currently AMEX:XLV is trading below 250 days moving average, tested but failed to penetrate the moving average on Jul-8, if it still cannot get above the 250 days moving average in the coming months, the downside pressure will materialize into an actual down trend. In summary, these are the important levels one should pay attention to: Downside support 118.75: Jun-13 new box bottom 109.74: Post covid peak before rallying to the upside Upside resistance 132.04: Jul-8 attempt of breaking 250 days moving average 143.42: Apr-8 new box top
AMEX:XLVLong
by geoffreyip523
$HUM Humana LT Chart - LEAP OptionsHumana fairly rangebound for the last six months. Tested ~$470 key resistance level six times unsuccessfully. Monitor for a breakthrough and close above this level. Once this occurs we could see an overdue strong move to the $600 area by 1H of 2024. Long Term Target: $580-$615 range by 1H '24 I plan to play this using LEAP options. I'm looking at the $450 and $500 Jan'24 calls. If you're looking to limit risk and capital outlay, I would consider a vertical call spread buying either the $450 or $500 call and selling the $600. Note: This is NOT investment advice. This is opinion only.
NYSE:HUMLong
by Triple_Barrel_Capital